Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2019
Reporting Period: Quarter ended June 30, 2019
Context: The filing serves to announce the Company's results of operations and financial condition for the second quarter of 2019 via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only indicates that results for the quarter ended June 30, 2019, were announced.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the information contained in Item 2.02 and the accompanying press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933.
Guidance and Risks: No specific guidance, outlook, risks, contingencies, or unusual items are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2019) for actual financial figures and operational updates.
- Verify the Company's status as an emerging growth company (indicated as yes in the filing).
- Confirm the trading symbol (SPRO) and exchange (The Nasdaq Global Select Market).
- Note the legal disclaimer that the results announced in this 8-K are not incorporated by reference into other SEC filings.